| HRA000428
(Controlled Access)
|
Breast cancer is the most common cancer diagnosed among women (excluding skin cancers) and is the second leading cause of cancer death among women after lung cancer. Neoadjuvant trials provide endpoints, such as pathological complete response (pCR) to treatment, that potentially translate into meaningful improvements in overall survival and disease-free survival.In response to the clinical needs that the outcome of neoadjuvant chemotherapy for breast cancer are difficult to predict, our project intend to integrate of multi-dimensional information such as radiomics, genomics and clinicopathology data and screen out some imaging omics profile and gene molecular markers that highly correlated with breast cancer Neoadjuvant efficacy and construct an imaging genomics prediction model. |
